Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director · Chief Executive Officer | July 09, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date July 09, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,306,108 |
Reported balance
After 2026-07-09 transaction · row 1
1 source rowRow 1 · 2026-07-09 · Sale · Disposed 67,971 · Balance 1,306,108 F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 9, 2026 23:22 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 67,971 | $6.96 | $473,329.65 |
DisclosureSEC source: 0001493152-26-032744 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,306,108 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 31,916 | $5.30 | $169,288.85 |
DisclosureSEC source: 0001493152-26-028020 · ownership.xml · nonDerivative · entry 2 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,374,079 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 24,428 | $5.43 | $132,631.83 |
DisclosureSEC source: 0001493152-26-028020 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,405,995 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 01:03 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 29,985 | $4.38 | $131,481.23 |
DisclosureSEC source: 0001493152-26-014418 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,430,423 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.31 to $4.43 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 01:33 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 69,832 | $5.33 | $372,267.41 |
DisclosureSEC source: 0001493152-26-003283 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,460,408 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 365,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002887 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,530,240 F1 · shares: The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029. Read SEC document |
| December 29, 2025 Filed Dec 29, 2025 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,000 | $5.31 | $132,740.00 |
DisclosureSEC source: 0001493152-25-029384 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,164,818 F1 · kind: The reported sale of 25,000 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.215 to $5.41 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 16, 2025 Filed Oct 16, 2025 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 249 | $5.49 | $1,365.77 |
DisclosureSEC source: 0001493152-25-018311 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,189,818 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,000 | $5.24 | $130,930.00 |
DisclosureSEC source: 0001493152-25-016543 · ownership.xml · nonDerivative · entry 2 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,190,067 F3 · kind: The reported sale of 25,000 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.2725 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 19,274 | $5.39 | $103,954.32 |
DisclosureSEC source: 0001493152-25-016543 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,215,067 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 69,420 | $5.86 | $406,502.69 |
DisclosureSEC source: 0001641172-25-018606 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234,341 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 22:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 50,676 | $6.76 | $342,569.76 |
DisclosureSEC source: 0001641172-25-014172 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,303,761 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.76 to $6.79 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 885 | $6.24 | $5,522.40 |
DisclosureSEC source: 0001641172-25-013428 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,354,437 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 23:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,000 | $4.78 | $119,500.00 |
DisclosureSEC source: 0001641172-25-001922 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,355,322 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2024. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.71 to $4.81 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:54 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 476,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-003463 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,380,322 F1 · shares: The restricted stock will vest one-third on each of January 21, 2026, January 21, 2027 and January 21, 2028. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 251 | $6.54 | $1,641.54 |
DisclosureSEC source: 0001493152-24-041421 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903,887 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 28, 2024 Filed Sep 30, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 18,798 | $5.89 | $110,720.22 |
DisclosureSEC source: 0001493152-24-038802 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,138 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 424,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026642 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922,936 F1 · shares: The restricted stock will vest one-third on each of July 8, 2025, July 8, 2026 and July 8, 2027. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 38,621 | $4.52 | $174,566.92 |
DisclosureSEC source: 0001493152-24-023124 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,936 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 703 | $4.38 | $3,079.14 |
DisclosureSEC source: 0001493152-24-022756 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,557 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 12:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon Stock | 10,000 | $3.20 | $32,000.00 |
DisclosureSEC source: 0001493152-24-016853 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,260 Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 13:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon Stock | 20,000 | $4.39 | $87,800.00 |
DisclosureSEC source: 0001493152-24-005208 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,260 F1 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.34 to $4.40 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 181 | $4.14 | $749.34 |
DisclosureSEC source: 0001493152-23-037500 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,260 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 21:25 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 13,290 | $3.93 | $52,229.70 |
DisclosureSEC source: 0001493152-23-034916 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,441 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 11:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon Stock | 20,000 | $4.07 | $81,400.00 |
DisclosureSEC source: 0001493152-23-034741 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,731 F1 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.88 to $4.19 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 336,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-020417 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,731 F1 · shares: The restricted stock will vest one-third on each of June 5, 2024, June 5, 2025 and June 5, 2026. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 827 | $3.06 | $2,530.62 |
DisclosureSEC source: 0001493152-23-020291 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,905 F1 · shares: Represents the number of shares that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock and does not represent a sale. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 207 | $4.30 | $890.10 |
DisclosureSEC source: 0001493152-22-028650 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,732 F1 · shares: Represents the number of shares that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock and does not represent a sale. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 155,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027279 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,939 F1 · shares: The restricted stock will vest 25% on each of September 28, 2023, September 28, 2024, September 28, 2025 and September 28, 2026. Read SEC document |
| June 01, 2022 Filed Jun 17, 2022 20:13 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 81,525 | $0.16 | $13,044.00 |
DisclosureSEC source: 0001493152-22-017159 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,475 F1 · kind: Represents the number of shares of that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock and does not represent a sale. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-21-025690 · ownership.xml · derivative · entry 2 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-10-15 F2 · derivative.exercise_date: The options will vest 25% on October 15, 2022, and in 36 equal monthly installments thereafter. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025690 · ownership.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 F1 · shares: The restricted stock will vest 25% on each of October 15, 2022, October 15, 2023, October 15, 2024 and October 15, 2025. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 01:06 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001567619-21-011667 · doc1.xml · derivative · entry 3 Seshadri Vishwas · CIK 0001865131 · SVP, Head of Res./Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-06-01 F3 · derivative.exercise_date: The options will vest 25% on June 1, 2022, and in 36 equal monthly installments thereafter. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 01:06 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011667 · doc1.xml · nonDerivative · entry 2 Seshadri Vishwas · CIK 0001865131 · SVP, Head of Res./Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F2 · shares: The restricted stock will vest 100% on each of June 1, 2022. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 01:06 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011667 · doc1.xml · nonDerivative · entry 1 Seshadri Vishwas · CIK 0001865131 · SVP, Head of Res./Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: The restricted stock will vest 25% on each of June 1, 2022, June 1, 2023, June 1, 2024 and June 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.